CTOR
Citius OncologyยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
CTOR Profile
Citius Oncology, Inc.
New targeted tumor therapy development company
Life Science Tools and Services
03/01/2021
12/08/2022
NASDAQ Stock Exchange
0
09-30
Common stock
11 Commerce Drive, First Floor, Cranford, NJ 07016
--
Citius Oncology, Inc. (formerly TenX Keane Acquisition) was incorporated in the Cayman Islands on March 1, 2021, and was relocated and naturalized as a Delaware company on August 5, 2024. Citius Oncology will serve as a platform to develop and commercialize novel targeted tumor therapies. In August 2024, its main asset, LYMPHIR, received FDA approval for the treatment of adult patients with relapsed or refractory CTCL who have received at least one systemic treatment.
